NORCURON Drug Patent Profile
✉ Email this page to a colleague
When do Norcuron patents expire, and what generic alternatives are available?
Norcuron is a drug marketed by Organon Usa Inc and is included in one NDA.
The generic ingredient in NORCURON is vecuronium bromide. There are six drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the vecuronium bromide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Norcuron
A generic version of NORCURON was approved as vecuronium bromide by MEITHEAL on August 25th, 1999.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for NORCURON?
- What are the global sales for NORCURON?
- What is Average Wholesale Price for NORCURON?
Summary for NORCURON
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 84 |
| Clinical Trials: | 3 |
| Patent Applications: | 1,721 |
| DailyMed Link: | NORCURON at DailyMed |
Recent Clinical Trials for NORCURON
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| China Medical University Hospital | Phase 4 |
| RenJi Hospital | Phase 4 |
| Tongji Hospital | Phase 4 |
US Patents and Regulatory Information for NORCURON
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Organon Usa Inc | NORCURON | vecuronium bromide | INJECTABLE;INJECTION | 018776-002 | Apr 30, 1984 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Organon Usa Inc | NORCURON | vecuronium bromide | INJECTABLE;INJECTION | 018776-003 | Jan 3, 1992 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for NORCURON
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Organon Usa Inc | NORCURON | vecuronium bromide | INJECTABLE;INJECTION | 018776-002 | Apr 30, 1984 | ⤷ Sign Up | ⤷ Sign Up |
| Organon Usa Inc | NORCURON | vecuronium bromide | INJECTABLE;INJECTION | 018776-003 | Jan 3, 1992 | ⤷ Sign Up | ⤷ Sign Up |
| Organon Usa Inc | NORCURON | vecuronium bromide | INJECTABLE;INJECTION | 018776-003 | Jan 3, 1992 | ⤷ Sign Up | ⤷ Sign Up |
| Organon Usa Inc | NORCURON | vecuronium bromide | INJECTABLE;INJECTION | 018776-002 | Apr 30, 1984 | ⤷ Sign Up | ⤷ Sign Up |
| Organon Usa Inc | NORCURON | vecuronium bromide | INJECTABLE;INJECTION | 018776-002 | Apr 30, 1984 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for NORCURON
See the table below for patents covering NORCURON around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Argentina | 228728 | PROCEDIMIENTO PARA EVITAR LA HIDROLISIS DE UN GRUPO 3ALPHA-ACILOXI EN UN COMPUESTO 5ALPHA-ANDROSTANO | ⤷ Sign Up |
| Philippines | 16041 | IMPROVED 2BETA,16BETA-BIS-PIPERIDINO ANDROSTANES | ⤷ Sign Up |
| Ireland | 791593 | ⤷ Sign Up | |
| Ireland | 50376 | ACID ADDITION SALTS OF 16B-MONOQUATERNARY AMMONIUM DERIVATIVES OF 2B,16B-BIS-PIPERIDINO-ANDROSTANES AND PHARMACEUTICAL PREPARATIONS CONTAINING SAME | ⤷ Sign Up |
| Hungary | 181847 | PROCESS FOR PRODUCING ACID ADDITIONAL SALTS OF 16-BETA-MONO-QUATERNER-AMMONIUM DERIVATIVES OF 2-BETA,16-BETA-BIS-PIPERIDINO-ANDROSTANES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AS ACTIVE AGENTS | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
